Souhaitez-vous accéder aux communiqués récents ?

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16,...

- Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted...

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - -...

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and...

FDA confirmed givastomig’s potential eligibility for an accelerated approval pathwayNovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective...

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results...

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic...

WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral...

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- A groundbreaking advancement in ophthalmology has been achieved as Super Vision Technology announced that its i-NYS (Extraocular Neuromuscular Stimulator...

Doctomatic Appoints Tech Veteran Bill Josko as Head of Americas to Scale AI-Driven Remote Patient Monitoring

STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...

ZUG, Switzerland, 16 March, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical...

ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address...

Modification de la composition du Conseil d'Administration Fleurieux-sur-l’Arbresle - France - le 16 mars 2026 à 8h. SAFE Group annonce des évolutions significatives au sein de son Conseil...

Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial...

NEW YORK, March 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October...

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application...

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025? Affected uniQure N.V. Investor Summary Who: uniQure N.V. (NASDAQ: QURE)What: Securities fraud class action lawsuit...

New York City, NY, March 14, 2026 (GLOBE NEWSWIRE) -- For anyone who has been thinking about fixing their smile, whether due to staining from years of coffee drinking, a chip that has been a...

Find out more about ProvaDent and how it works exactly! New York City, NY, March 14, 2026 (GLOBE NEWSWIRE) --  Dental wellness, oral health, and preventive healthcare have become popular topics...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their Options If you purchased or...

AgelessRx 2026 consumer analysis: longevity telehealth platform, compounded NAD+, GLP-1, semaglutide, metformin, pricing, and prescription process reviewed

NeuroGenica nerve support claims evaluated: 2026 report on ingredient science, Schwann cell context, and what to verify before buying.

Septifix septic tank treatment tablets use oxygen-releasing aerobic bacteria technology. 2026 consumer report on formula, pricing, and homeowner considerat

Vanish DrySerum nanofiber acne mask claims evaluated: barrier repair technology, ingredient research, & what consumers should verify before buying in 2026.

Vitamin M brain supplement claims examined. 2026 consumer research report on Pineal Guardian X ingredients, melatonin science, and pineal gland health.

BENSALEM, Pa., March 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of...

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in the class action...

Calgary, AB , March 13, 2026 (GLOBE NEWSWIRE) -- Scott Gilbert and Brian Fehr, two friends who met twenty-eight years ago while receiving drug and alcohol treatment at the renowned Hazelden Betty...

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Roferon-a Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Roctavian Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "Rybrevant Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. ...

Investors who lost money in SLNO after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

New class action for Corcept (CORT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/21/2026.

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

PALO ALTO, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing,...

Investors who lost money in CORT after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA...

Junshi Biosciences announced its financial results for the full year of 2025 and provided corporate updates.

INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or...